Tvardi Therapeutics (NASDAQ:TVRD) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen cut shares of Tvardi Therapeutics (NASDAQ:TVRD) from a sell rating to a strong sell rating in a research note published on Sunday.

TVRD has been the subject of several other research reports. BTIG Research lowered their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial upgraded Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a report on Wednesday, July 8th. UBS Group raised shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective on the stock in a research report on Wednesday, July 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. Finally, HC Wainwright assumed coverage on shares of Tvardi Therapeutics in a research report on Monday, June 8th. They issued a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Stock Performance

TVRD opened at $1.82 on Friday. The stock has a fifty day moving average price of $2.32 and a 200 day moving average price of $3.03. Tvardi Therapeutics has a 1 year low of $1.50 and a 1 year high of $43.65. The stock has a market cap of $24.28 million, a price-to-earnings ratio of -0.65 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, sell-side analysts forecast that Tvardi Therapeutics will post -2.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several large investors have recently made changes to their positions in TVRD. Quadrature Capital Ltd acquired a new position in shares of Tvardi Therapeutics during the fourth quarter worth approximately $90,000. Russell Investments Group Ltd. boosted its position in shares of Tvardi Therapeutics by 1,351.5% in the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock valued at $69,000 after acquiring an additional 14,866 shares during the period. HRT Financial LP acquired a new stake in shares of Tvardi Therapeutics in the fourth quarter worth $47,000. Goldman Sachs Group Inc. grew its stake in shares of Tvardi Therapeutics by 37.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock worth $142,000 after acquiring an additional 9,102 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in Tvardi Therapeutics during the second quarter worth $80,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.